Addex Therapeutics
ADXN
5 hedge funds and large institutions have $3.46K invested in Addex Therapeutics in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0.02% more ownership
Funds ownership: 0.01% → 0.02% (+0.02%)
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
96% less capital invested
Capital invested by funds: $96.2K → $3.46K (-$92.8K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$639 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$86.2K |
| 2 |
GI
GAMMA Investing
Foster City,
California
|
-$8.67K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GI
1
GAMMA Investing
Foster City,
California
| $1.14K | -$8.67K | -1,072 | -90% |
|
2
Morgan Stanley
New York
| $941 | – | – | – |
|
|
3
JP Morgan Chase
New York
| $699 | +$639 | +79 | New |
|
4
RhumbLine Advisers
Boston,
Massachusetts
| $637 | – | – | – |
|
|
SS
5
SBI Securities
Tokyo,
Japan
| $47 | – | – | – |
|
|
6
Citadel Advisors
Miami,
Florida
| – | -$86.2K | -11,741 | Closed |
|
ADXN Hedge Fund Activity: Q2 2025 in Review
5 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Addex Therapeutics (ADXN) for Q2 2025, worth a combined $3.46K — down 96% from $96.2K a quarter earlier.
Fund positioning in ADXN was balanced in Q2 2025: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $639. The largest seller was Citadel Advisors, exiting entirely with an estimated $86.2K sold.
- 5 institutional investors held Addex Therapeutics (ADXN) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $3.46K of Addex Therapeutics stock for Q2 2025, down 96% quarter-over-quarter.
- 1 fund opened new Addex Therapeutics positions in Q2 2025 and 1 closed out, a net change of 0 holders.
- The largest Addex Therapeutics buyer in Q2 2025 was JP Morgan Chase, an estimated $639 added.
- The largest Addex Therapeutics seller in Q2 2025 was Citadel Advisors, an estimated $86.2K sold.
Based on aggregated 13F filings for Q2 2025.